Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich, Thomas Guldager Lauridsen, Hong Yuan et al.|The Lancet|2022

Cited by 223